LAVA Therapeutics N.V

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called V9V2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy...

Biotechnology,gamma delta t cells,bispecific antibodies,and oncology

Lava therapeutics n.v operates in the Biotechnology research industry.

Lava therapeutics n.v's revenue is 1m - 10m

Lava therapeutics n.v has 11 - 50 employees.